Chronic Myeloid Leukemia Features Archive

Chronic Myeloid Leukemia EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.

General Oncology Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

General Oncology Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Chronic Myeloid Leukemia 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.

General Oncology The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the important patient factors that can be missed via standard data collection methods for those with cancer.

Chronic Myeloid Leukemia Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.

General Oncology Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

General Oncology Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

General Oncology Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Chronic Myeloid Leukemia Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.

General Oncology Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Hematologic Cancers Pleural Effusions More Common Than Previously Thought in Dasatinib-Treated Leukemias

Pleural Effusions More Common Than Previously Thought in Dasatinib-Treated Leukemias

With newer treatments, alternatives to dasatinib exist, if needed.

General Oncology Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

General Oncology Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Chronic Myeloid Leukemia Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.

General Oncology FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

General Oncology Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Chronic Myeloid Leukemia The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.

General Oncology Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Chronic Myeloid Leukemia Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

A large, long-term study found a 97% event-free survival rate at 18 months.

General Oncology Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

General Oncology Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Chronic Myeloid Leukemia ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.

General Oncology ARID1A Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

General Oncology Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

General Oncology Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

General Oncology Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Chronic Myeloid Leukemia Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.

Prostate Cancer Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Chronic Myeloid Leukemia Pediatric CML: Life-Long Considerations With TKI Therapy

Pediatric CML: Life-Long Considerations With TKI Therapy

Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.

General Oncology Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

General Oncology The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

General Oncology HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

General Oncology Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

General Oncology Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Side Effect Management Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Chronic Myeloid Leukemia Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia

One study's results may be especially relevant for patients eligible for treatment discontinuation.

General Oncology Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

General Oncology Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Chronic Myeloid Leukemia CML: Managing TKI-Related Toxicity To Yield the Best Outcomes

CML: Managing TKI-Related Toxicity To Yield the Best Outcomes

Preparing patients for treatment toxicity is important for ensuring that mild or moderate reactions do not undermine adherence.

General Oncology Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Side Effect Management Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

General Oncology Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

General Oncology Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Chronic Myeloid Leukemia Chronic Myeloid Leukemia: Choosing A TKI

Chronic Myeloid Leukemia: Choosing A TKI

Clinical trial data regarding deep molecular response outcomes suggest that dasatinib and nilotinib are superior to the first-generation TKI, imatinib.

Renal Cell Carcinoma Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances

Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances

Access to treatment should be considered as important as the research leading to clinical improvements.

Chronic Myeloid Leukemia Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML?

Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML?

Among female patients with CML, fertility preservation with ovarian stimulation can be challenging if patients require continuation of TKIs until HSCT.

General Oncology Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

General Oncology Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

General Oncology Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

General Oncology Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

General Oncology Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

General Oncology The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Chronic Myeloid Leukemia Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival?

Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival?

Although cytogenetic abnormalities that arise during the course of CML are prevalent in later stages of the disease and are associated with a poorer prognosis, as many as 10% to 12% of patients exhibit ACAs at diagnosis.

General Oncology Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

General Oncology Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

General Oncology Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

Chronic Myeloid Leukemia Cost, Insurance Status May Affect Patient Adherence to TKI Therapy for CML

Cost, Insurance Status May Affect Patient Adherence to TKI Therapy for CML

Although TKI therapy is highly effective, it is expensive, and may cost $146,000 per year on average if a patient is uninsured. High expenses make it difficult even for insured patients to meet their copayments and coinsurance costs.

Hematologic Cancers Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs

Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" implications for patients and their families. But these cancer immunotherapies might offer an excellent value for clinical oncology, proponents claim.

General Oncology Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

General Oncology Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Chronic Myeloid Leukemia Understanding Blast Phase Chronic Myeloid Leukemia

Understanding Blast Phase Chronic Myeloid Leukemia

A new study finds some hopeful signs of progress in understanding blast phase CML, which is typically associated with poor outcomes.

General Oncology Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

Chronic Myeloid Leukemia In Focus: Ponatinib for Chronic Myeloid Leukemia

In Focus: Ponatinib for Chronic Myeloid Leukemia

Ponatinib is highly effective among patients with CML, but the optimal dose is still being determined. Current trials are evaluating an initial dose of 30 mg, with a reduction to 15 mg when a response is achieved.

Chronic Myeloid Leukemia Selecting A TKI for Chronic Myeloid Leukemia

Selecting A TKI for Chronic Myeloid Leukemia

TKI selection in the first line is based on risk score and TKI toxicity profile as well as the patient's age, ability to tolerate therapy, and comorbid conditions.

General Oncology Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

General Oncology Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

General Oncology Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

General Oncology Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

General Oncology Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

General Oncology Dermatomyositis and Cancer Risk

Dermatomyositis and Cancer Risk

Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.

Chronic Myeloid Leukemia TKI Discontinuation for Patients With CML Could Save Billions

TKI Discontinuation for Patients With CML Could Save Billions

With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.

Chronic Myeloid Leukemia CML: Patient Study Links Insurance Status at Diagnosis and Overall Survival

CML: Patient Study Links Insurance Status at Diagnosis and Overall Survival

Chronic myeloid leukemia patient outcome study finds high correlation between insurance status at diagnosis and overall patient survival.

General Oncology Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.

General Oncology Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

General Oncology Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

General Oncology Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.

General Oncology Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

Chronic Myeloid Leukemia Atypical Chronic Myeloid Leukemia: Current Research and Treatment Strategies

Atypical Chronic Myeloid Leukemia: Current Research and Treatment Strategies

Strategies that work for patients with CML fail for aCML cases, though some new research is promising.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Chronic Myeloid Leukemia Pediatric Chronic Myeloid Leukemia: Targeting Treatment

Pediatric Chronic Myeloid Leukemia: Targeting Treatment

Researchers argue that children with CML should receive different treatments than adults, which may mitigate long-term side effects.

General Oncology Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.

General Oncology Incorporating Evolutionary Theory Into Oncology

Incorporating Evolutionary Theory Into Oncology

Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.

General Oncology Industry Payments Influence Research, Prescribing, and Advocacy

Industry Payments Influence Research, Prescribing, and Advocacy

Clinical trial investigators who receive drug industry funding are about 3.5 times as likely to find positive results as trials led by scientists who did not receive industry payments.

General Oncology Treeomics: A Mathematical Tool for Predicting Metastases

Treeomics: A Mathematical Tool for Predicting Metastases

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.

Chronic Myeloid Leukemia CD86+ pDCs: A Marker for Treatment-free Remission in Chronic Myeloid Leukemia?

CD86+ pDCs: A Marker for Treatment-free Remission in Chronic Myeloid Leukemia?

CD86-positive pDCs are known to regulate T cell activation, and previous data suggest that T cells can control CML.

Chronic Myeloid Leukemia Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future

Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future

The cost of treating CML can be crippling, and it's unclear whether future approvals or policies will improve the financial toxicity associated with the disease.

General Oncology ASCO Advance of the Year: Immunotherapy 2.0

ASCO Advance of the Year: Immunotherapy 2.0

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."

General Oncology Do Clinical Trials Overstate New Cancer Drugs' Survival Benefits?

Do Clinical Trials Overstate New Cancer Drugs' Survival Benefits?

Experts disagree about whether success in clinical trials translates to success in real world treatment settings.

Chronic Myeloid Leukemia Ponatinib: Black Box Warning and Drug Interactions

Ponatinib: Black Box Warning and Drug Interactions

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.

Chronic Myeloid Leukemia TKI Discontinuation and Chronic Myeloid Leukemia

TKI Discontinuation and Chronic Myeloid Leukemia

TKIs offer the possibility of durable responses for patients with CML, though it is unclear whether discontinuation is feasible.

General Oncology Vitamin D and Cancer: An Unclear Relationship

Vitamin D and Cancer: An Unclear Relationship

According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.

General Oncology Basket Trials: Advantages and Limitations

Basket Trials: Advantages and Limitations

Basket trials offer a cost-effective option to evaluate targeted agents in multiple malignancies, but it is important to be aware of their limitations.

General Oncology The Dashboard of Happiness

The Dashboard of Happiness

Dr Barbara Burtness of Yale University's School of Medicine discusses the relationship between happiness and clinical practice in oncology.

General Oncology Survival After Pediatric Cancer: Reducing the Lifetime Burden

Survival After Pediatric Cancer: Reducing the Lifetime Burden

A study of self-reported health status shows the need for physicians to consider the overall well-being of pediatric cancer survivors, for life.

ASH 2016 A Glimpse of ASH

A Glimpse of ASH

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

General Oncology Determining the Role of Gender in Oncology Trial and Treatment Outcomes

Determining the Role of Gender in Oncology Trial and Treatment Outcomes

Differences between the sexes are known in a variety of cancers, but the reasons remain unclear.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs